RETINALAMIN® activates retinal cells reserves increasing cell survivability and regenerative capacity when retina and optic nerve has been damaged. Retinalamin increases metabolism and blood flow, optimizes vascular permeability in eyes. It improves and stabilizes visual functions (visual acuity, low-light eyesight, visual field extension). The data is supported by specific retina and optic nerve studies. Pharmaceutical Company GEROPHARM is a sole manufacturer of Retinalamin. The drug is manufactured using the Company's own patented technology.

USES

• Compensated Primary Ppen-Angle Glaucoma
• Diabetic Retinopathy
• Post-Traumatic and Post-Inflammatory Central Retinal Dystrophy (Macular Dystrophy)
• Central Retinal Dystrophy (Macular Dystrophy)
• Myopia (Within Comprehensive Treatment)
• Central and Peripheral Tapetoretinal Abiotrophy

GUARANTEE & EXPIRY DATE
Original from the Russian Geropharm.
All packs are air tight sealed and expire up to 08.2024.

DESCRIPTION
Retinoprotectors are agents that protect retina from damage caused by exogenous and endogenous forces thus safeguarding eyesight from getting worse. Searching for new agents for retinal protection is a complicated process which requires integrated efforts of therapists, biologists and pharmacologists. Special attention should be given to peptide drugs. The benefits of these drugs are tissue specificity, absence of significant side-effects, short-course treatment and long-term clinical effect. Retinalamin® is an example of successful drug development based on these principles. The effecacy of Retinalamin® has been proven at the cellular and molecular levels. Retinal injuries may be caused by various factors and have different disease patterns, however, they are all accompanied by death of retinal neurons due to pathological processes with the similar molecular mechanisms. Among those mechanisms the most predominant one is excitotoxicity caused by overstimulation of glutamate receptors followed by the influx of calcium ions. Excessive Ca2+ concentration triggers processes of cell death via necrosis or apoptosis.

PACKAGING & DOSAGE
Retinalamin comes in lyophilisate preparation of solution for intramuscular and parabulbar injections.
Active ingredient: Retinalamin 5 mg (complex of water-soluble polypeptide fractions)
 Excipients: Glycine 17 mg (stabilizer)

DOSAGE
In adults with diabetic retinopathy, post-traumatic and post-inflammatory central retinal dystrophy, central and peripheral tapetoretinal abiotrophy: parabulbar or intramuscular injections of 5-10 mg once a day. Treatment duration is 5-10 days; if necessary, repeated after 3-6 months.
In patients with compensated primary open-angle glaucoma: parabulbar or intramuscular injections of 5 mg once a day. Treatment duration is 10 days; if necessary, repeated after 3-6 months. In patients with myopia: parabulbar injections of 5 mg once a day. Treatment duration is 10 days. It is recommended to combine with angioprotectorsand B group vitamins.
Dissolve Retinalamin® lyophilisate in 1-2 ml of water for injections, in 0.9 % solution of sodium chloride, or in 0.5 % solution of procaine (novocaine), directing the needle toward the side of the vial to avoid foaming.
In children at the age of 1 – 5 years with post-traumatic and post-inflammatory central retinal dystrophy, central and peripheral tapetoretinal abiotrophy: parabulbar or intramuscular injections of 2.5 mg once a day.
In children at the age of 6 – 18 years with retina central dystrophy of post-traumatic and post-inflammatory origin, central and peripheral tapetoretinal abiotrophy: parabulbar or intramuscular injections of 2.5 – 5.0 mg once a day.
Dissolve Retinalamin® lyophilisate in 1-2 ml of 0.9 % solution of sodium chloride, directing the needle toward the side of the vial to avoid foaming. Treatment duration is 10 days; if necessary, repeated after 3-6 months.

SIDE EFFECTS AND PRECAUTIONS
No reported cases of adverse effects. Allergic reactions are possible in case of individual intolerance to any component of medication.

STORAGE
Store in dry protected from light place, at 2–20 °C. Supplied as Lyophilisate for preparation of solution for intramuscular and parabulbar injections, 5 mg.

QUESTIONS?
Ask us any questions about Retinalamin.